Trials · 2019 · 22 citations · 23 references
Life SciencesNutritional SciencesPharmacologyHuman NutritionInflammationMetabolic RegulationAdipose TissueAnti-inflammatory PharmacologyBioactive Food ComponentsLipid MetabolismMetabolic InflammationWeight ManagementAdiponectin SignalingAdipose Tissue DysfunctionAdipose Tissue Gene Expression ResponsesInflammation-related Gene ExpressionObesity-induced InflammationProtein Expression Levels
BACKGROUND: Obesity is a major public health problem in recent decades. The accumulation of excessive fat promotes inflammatory status. Meanwhile, herbal products are marketed for their weight-loss properties, such as Nigella sativa (N. Sativa) which has been used for centuries to treat rheumatoid arthritis, diabetes, and asthma; recently, the anti-obesity characteristics of N. sativa have also been indicated. However, the exact mechanisms and cellular-related pathways are still unclear. Thus, we will aim to assess the effects of oral N. sativa on the gene expression of inflammatory and adipogenesis-related factors, including TNF-α, PPAR-γ, and adiponectin as well as assessing their serum concentrations among obese and overweight individuals. METHODS: will be recruited from the Obesity Clinic in Shahid Sadoughi University of Medical Sciences and will be assessed for eligibility against inclusion criteria. They will be randomly assigned into two groups to receive either two capsules of N. sativa or two capsules of placebo per day for eight weeks (each capsule contains 1000 mg of N. sativa or placebo). There will be a four-week wash-out period and then participants will receive the reverse supplements for another eight weeks. Biochemical assessments and gene expressions (using real-time polymerase chain reaction) will be conducted at the beginning and at the end of every intervention period. DISCUSSION: The present study will investigate the probable cellular pathways for the anti-obesity effects of N. sativa in overweight/obese women. TRIAL REGISTRATION: Iranian Registry of Clinical Trials, IRCT20180528039884N1 . Registered on 2nd of July, 2018.
23
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
A.-W. Chan, Jennifer Tetzlaff, Peter C Gøtzsche et al. · BMJ · 2013 · 7.1K citations · Full text
Obesity: definition, comorbidities, causes, and burden.
Caroline M. Apovian · PubMed · 2016 · 905 citations
Takara L. Stanley, Markella V. Zanni, Stine Johnsen et al. · The Journal of Clinical Endocrinology & Metabolism · 2010 · 319 citations
Navdeep Chehl, Galina Chipitsyna, Qiaoke Gong et al. · HPB · 2009 · 313 citations · Full text
Medicine, Oncology, Pharmacology +7